Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.
2018 ◽
Vol 36
(15_suppl)
◽
pp. 6615-6615
2017 ◽
Vol 11
(6)
◽
pp. 204
◽
2019 ◽
Vol 25
(2)
◽
pp. 225-234
◽
2018 ◽
Vol 14
(10)
◽
pp. 580-587
◽
Keyword(s):
Keyword(s):